Kiniksa Pharmaceuticals International, plc Segments Disclosure
17. Segment Information and Geographic Data
The Company manages its operations as a operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is on developing and commercializing novel therapies that target cardiovascular diseases with significant unmet medical need. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer. The Company’s CODM reviews consolidated operating results and decides how to allocate resources based on net income that also is reported on the income statement as consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes net income to make key decisions about how to allocate resources across the Company’s commercial product and development programs.
The following table presents selected financial information with respect to the Company’s single operating segment for the years ended December 31, 2025, 2024 and 2023:
Years Ended | |||||||||
December 31, | |||||||||
| 2025 | 2024 | | 2023 | |||||
Revenue: | |||||||||
Product revenue, net | $ | 677,564 | $ | 417,029 | $ | 233,176 | |||
License and collaboration revenue | - | 6,210 | 37,083 | ||||||
Total revenue | 677,564 | 423,239 | 270,259 | ||||||
Operating expenses: | |||||||||
Cost of goods sold | 77,673 | 60,910 | 33,407 | ||||||
Collaboration expenses | 229,545 | 128,311 | 56,524 | ||||||
Direct research and development expenses by program: | |||||||||
ARCALYST | 1,040 | 1,080 | 2,628 | ||||||
KPL-387 | 47,265 | 11,221 | 2,537 | ||||||
KPL-1161 | 4,198 | 581 | - | ||||||
Abiprubart | 6,122 | 59,459 | 28,388 | ||||||
Vixarelimab | 44 | 1,530 | 7,717 | ||||||
Unallocated research and development expenses | 38,184 | 37,752 | 34,827 | ||||||
Selling, general and administrative | 196,272 | 168,011 | 129,427 | ||||||
Total operating expenses | 600,343 | 468,855 | 295,455 | ||||||
Other income, net (1) | 11,647 | 9,464 | 8,544 | ||||||
Income (loss) before income taxes | 88,868 | (36,152) | (16,652) | ||||||
Benefit (provision) for income taxes | (29,863) | (7,041) | 30,736 | ||||||
Net income (loss) | $ | 59,005 | $ | (43,193) | $ | 14,084 | |||
Other significant non-cash items: |
|
|
| ||||||
Share-based compensation expense | $ | 37,003 | $ | 30,693 | $ | 27,149 | |||
Non-cash lease expense | 3,666 | 3,136 | 3,054 | ||||||
Deferred income taxes | 13,002 | 8,132 | (33,788) | ||||||
| (1) | Includes interest income of $11,636, $9,036 and $8,227 for the years ended December 31, 2025, 2024 and 2023 respectively. |
The following table presents total revenue by geographic region of the customer for years ended December 31, 2025, 2024 and 2023:
Years Ended | |||||||||
December 31, | |||||||||
2025 | 2024 | | 2023 | ||||||
Revenue: | |||||||||
United States | $ | 676,750 | $ | 421,434 | $ | 269,772 | |||
United Kingdom | 814 | 930 | 487 | ||||||
Rest of world | - | 875 | - | ||||||
Total revenue | $ | 677,564 | $ | 423,239 | $ | 270,259 | |||
The following table presents property and equipment, net by geographic region:
Years Ended | ||||||
December 31, | ||||||
2025 | 2024 | |||||
Property and Equipment, net | ||||||
United States | $ | 1,608 | $ | 313 | ||
United Kingdom | 76 | 99 | ||||
Rest of world | 259 | 250 | ||||
Total property and equipment, net | $ | 1,943 | $ | 662 | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.